There are 2789 resources available
1355P - Monitoring tumor growth rate to predict immune checkpoint inhibitors’ treatment outcome in advanced NSCLC
Presenter: Filippo Dall'Olio
Session: ePoster Display
1356P - Cumulative incidence and baseline imaging patterns of brain metastases in advanced EGFR and ALK positive non-small cell lung cancer (NSCLC)
Presenter: Maisha Chowdhury
Session: ePoster Display
1357P - A deep radiomics approach to assess PD-L1 expression and clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A multicentric study
Presenter: Marion Tonneau
Session: ePoster Display
1307P - Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1–positive (TPS ≥50%), advanced NSCLC in Japan
Presenter: Yasushi Goto
Session: ePoster Display
1308P - Efficacy and safety of anti-PD-1 therapy plus anlotinib in previously treated advanced NSCLC
Presenter: Xin Lv
Session: ePoster Display
1309P - A multicenter phase I study of radium-223 (Ra-223) plus pembrolizumab in patients with stage IV non-small cell lung cancer (NSCLC)
Presenter: Martin Reck
Session: ePoster Display
1310P - Toripalimab combined with chemotherapy as second-line treatment of advanced non-small cell lung cancer (NSCLC): A single center retrospective study
Presenter: man Jiang
Session: ePoster Display
1311P - The role of inflammatory biomarkers in advanced non-small cell lung cancer patients treated with chemo-immunotherapy
Presenter: Emma Zattarin
Session: ePoster Display
1312P - Prognostic impact of KRAS status in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor monotherapy
Presenter: Giacomo Pelizzari
Session: ePoster Display
1255P - Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)
Presenter: Niels Reinmuth
Session: ePoster Display